{
    "id": "medical_genetics-007",
    "question": "Asp235Phe in a molecular report indicates that:",
    "options": {
        "A": "asparagine has been replaced by phenylalanine.",
        "B": "phenylalanine has been replaced by asparagine.",
        "C": "aspartic acid has been replaced by phenylalanine.",
        "D": "phenylalanine has been replaced by aspartic acid."
    },
    "answer": "C",
    "predict": "To answer this question, let's break down the process step by step. Step 1: Understand the mutation notation The mutation notation used in the molecular report is \"Asp235Phe\". This notation indicates that at position 235 of the protein sequence, an aspartic acid (Asp) has been replaced by a phenylalanine (Phe). Step 2: Analyze the options Now, let's analyze the options: A. asparagine has been replaced by phenylalanine. - This option is incorrect because asparagine is a different amino acid from aspartic acid. B. phenylalanine has been replaced by asparagine. - This option is incorrect because phenylalanine is the new amino acid, not asparagine. C. aspartic acid has been replaced by phenylalanine. - This option matches the notation \"Asp235Phe\", where aspartic acid (Asp) has been replaced by phenylalanine (Phe). D. phenylalanine has been replaced by aspartic acid. - This option is incorrect because phenylalanine is the new amino acid, not aspartic acid. Step 3: Choose the correct answer Based on the analysis, the correct answer is: {\"step_by_step_thinking\": \"To determine the correct answer, we need to understand the mutation notation and analyze the options. The notation indicates that at position 235 of the protein sequence, an aspartic acid has been replaced by a phenylalanine. Therefore, the correct answer is C. aspartic acid has been replaced by phenylalanine.\", \"answer_choice\": \"C\"}",
    "snippets": [
        {
            "id": "Pathology_Robbins_1780",
            "title": "Pathology_Robbins",
            "content": "Acquired genetic alterations, such as somatic mutations in cancer, are increasingly becoming a large focus area in molecular diagnostics laboratories, especially with the advent of targeted therapies. Although single gene tests (mutations of EGFR or BRAF, amplification of HER2) have been used for a while to inform treatment decisions, the advent of cost-effective next-generation sequencing approaches has now allowed interrogations of large numbers of coding genes (often in the 100s), as well as cancer-relevant translocations, in a single assay. The clinical team typically receives a \u201cgenomic report\u201d on the patient\u2019s cancer, including potential molecularly targeted treatment recommendations. Another major focus of molecular diagnostics has been the rapid identification of infectious diseases, such as suspected tuberculosis or virulent pathogens such as Ebola, using DNA-based approaches. In general, these approaches have cut down the time required for diagnosis from weeks to a matter of"
        },
        {
            "id": "InternalMed_Harrison_30528",
            "title": "InternalMed_Harrison",
            "content": "Sensory ataxic neuropathy and ophthalmoparesis (SANDO) with dysarthria (autosomal recessive) 7p21.3-p15.1 1p21-q23; deletion (in frame); V338E; G345V; T377M; allelic with SCA19; KCND3; Kv4.3 channels 20p13-12.3; prodynorphin (PDYN protein); missense R138S; L211S; R212W; R215C 19p13.3 18p11.22-q11.2; ATPase family gene 3like 2 (AFG3L2 protein) mutations: N432T; S674L; E691K; A694E; R702Q 4q34.3-q35.1; candidate gene ODZ3 16q22.1; associated with NEDD4 (BEAN) 20p13; large intronic expansion of GGCCTG (1500\u20132500); also phe265leu mutation; RNA gain of function; microRNA; MIR 1292 suppression 20p13;pro102leu; ala 117 val mutations; proteinase k resistant form PrP27-30 accumulates in brain; eponym: GerstmannStra\u00fcssler-Scheinker disease Glu200Lys mutation; increased octapeptide repeats; eponym: Creutzfeldt-Jakob disease 10q23.31; phosphatase and tensin homolog (PTEN); Cowden\u2019s; Lhermitte-Duclos syndrome 19p13.2; exon 21; missense ala570val; val606phe mutations 1p36.31-p36.23 13q14.2;"
        },
        {
            "id": "InternalMed_Harrison_30529",
            "title": "InternalMed_Harrison",
            "content": "Creutzfeldt-Jakob disease 10q23.31; phosphatase and tensin homolog (PTEN); Cowden\u2019s; Lhermitte-Duclos syndrome 19p13.2; exon 21; missense ala570val; val606phe mutations 1p36.31-p36.23 13q14.2; integral membrane protein 2B (ITM2B) 12p13.31 with CAG repeats (exonic) 9q13-q21.1 with intronic GAA repeats, in intron at end of exon 1"
        },
        {
            "id": "InternalMed_Harrison_30523",
            "title": "InternalMed_Harrison",
            "content": "type calcium channel subunit 3p14.1-p21.1 with CAG repeats (exonic); ataxin-7; subunit of GCN5, histone acetyltransferase-containing complexes; ataxin-7 binding protein; Cbl-associated protein (CAP; SH3D5) 13q21 with CTG repeats; noncoding; 3\u2018 untranslated region of transcribed RNA; KLHL1AS 22q13; pentanucleotide repeat ATTCT repeat; noncoding, intron 9 15q14-q21.3 by linkage 5q31-q33 by linkage; CAG repeat; protein phosphatase 2A, regulatory subunit B, (PPP2R2B); protein PP2A, serine/ threonine phosphatase 19q13.3-q14.4; potassium channel voltage-gated; KCNC3 19q-13.4; protein kinase C\u03b3 (PRKCG), missense mutations including in-frame deletion and a splice site mutation among others; serine/threonine kinase 3p24.2-3pter; inositol 1,4,5triphosphate receptor type 1 (ITPRI) 8q22.1-24.1 6q27; CAG expansion in the TATA-binding protein (TBP) gene 1p21-q21; KCND3; missense mutations; T352P; M373I; S390N; allelic with SCA22; overlaps with the locus of SCA22 11p13-q11; 260 kb duplication Ataxia"
        },
        {
            "id": "InternalMed_Harrison_4753",
            "title": "InternalMed_Harrison",
            "content": "Genetic and genomic approaches have proven invaluable for the detection of infectious pathogens and are used clinically to identify agents that are difficult to culture such as mycobacteria, viruses, and parasites, or to track infectious agents locally or globally. In many cases, molecular genetics has improved the feasibility and accuracy of diagnostic testing and is beginning to open new avenues for therapy, including gene and cellular therapy (Chaps. 90e and 91e). Molecular genetics has also provided the opportunity to characterize the microbiome, a new field that characterizes the population dynamics of bacteria, viruses, and parasites that coexist with humans and other animals (Chap. 86e). Emerging data indicate that the microbiome has significant effects on normal physiology as well as various disease states."
        },
        {
            "id": "Cell_Biology_Alberts_2758",
            "title": "Cell_Biology_Alberts",
            "content": "1.1 iris of the human eye Figure Q9\u20134 Fluorescent reporter protein designed to detect tyrosine phosphorylation (problem 9\u20139). (a) Domain structure of reporter protein. Four domains are indicated: CFp, YFp, tyrosine kinase substrate peptide, and a phosphotyrosine-binding domain. (B) Fret assay. YFp/CFp is normalized to 1.0 at time zero. the reporter was incubated in the presence (or absence) of abl and atp for the indicated times. Arrow indicates time of addition of a tyrosine phosphatase. (From a.Y. ting, k.h. kain, r.L. klemke and r.Y. tsien, Proc. Natl Acad. Sci. USA 98:15003\u201315008, 2001. With permission from national academy of sciences.) separated. When the CFP and YFP domains are brought close together, however, fluorescence resonance energy transfer (FRET) allows excitation of CFP to stimulate emission by YFP. FRET shows up experimentally as an increase in the ratio of emission at 526 nm versus 476 nm (YFP/ CFP) when CFP is excited by 434 nm light."
        },
        {
            "id": "InternalMed_Harrison_7703",
            "title": "InternalMed_Harrison",
            "content": "No \u201cnew\u201d low-frequency mutations were found using a panel of mutations involving the P13K/AKT pathway, MEK pathway, receptors, and downstream effectors. Nevertheless, it is possible that newer \u201cdeep sequencing\u201d techniques in select patients may yield consistent abnormalities."
        },
        {
            "id": "InternalMed_Harrison_24849",
            "title": "InternalMed_Harrison",
            "content": "The variety and complexity of the clinical manifestations of the many different PIDs strongly indicate that it is important to raise awareness of these diseases. Indeed, early diagnosis is essential for establishing an appropriate therapeutic regimen. Hence, patients with suspected PIDs must always be referred to experienced clinical centers that are able to perform appropriate molecular and genetic tests. A precise molecular 2113 diagnosisis notonlynecessary for initiating the mostsuitabletreatment, but is also important for genetic counseling and prenatal diagnosis."
        },
        {
            "id": "InternalMed_Harrison_29202",
            "title": "InternalMed_Harrison",
            "content": "CHAPTER 431e Disorders of Purine and Pyrimidine Metabolism Carbamylphosphate +Aspartic acid Orotic AcidUTP RNA CTP or dCTP RNA or DNA UMPUDPdUMP CMP Cytidine Uracil \u00b0-Alanine \u00b0-Aminoisobutyric acid TTP 1 2 3 4 5 5 DNA dTMP Thymidine Thymine Uridine 2 FIgURE 431e-4 Abbreviated scheme of pyrimidine metabolism. (1) Thymidine kinase, (2) dihydropyrimidine dehydrogenase, (3) thymidylate synthase, (4) UMP synthase, (5) 5\u2032-nucleotidase. CMP, cytidine-5\u2032-monophosphate; UMP, uridine-5\u2032-monophosphate; UDP, uridine-5\u2032-diphosphate; dUMP, deoxyuridine-5\u2032-monophosphate; dTMP, deoxythymidine-5\u2032-monophosphate; TTP, thymidine triphosphate; UTP, uridine triphosphate. individuals have some measurable enzyme activity (type II). Expression of the defect is similar in the two populations, as is the frequency of the heterozygous state (0.4\u20131.1 per 100). Allopurinol treatment prevents stone formation."
        },
        {
            "id": "InternalMed_Harrison_29104",
            "title": "InternalMed_Harrison",
            "content": "in the ALAD gene. To date, molecular studies of ADP patients have identified nine point mutations, two splice-site mutations, and a two-base deletion in the ALAD gene (Human Gene Mutation Database; www.hgmd.org). The parents in each case were not consanguineous, and the index cases had inherited a different ALAD mutation from each parent. Prenatal diagnosis of this disorder is possible by determination of ALA dehydratase activity and/or gene mutations in cultured chorionic villi or amniocytes."
        },
        {
            "id": "Surgery_Schwartz_4126",
            "title": "Surgery_Schwartz",
            "content": "BG. Molecular and genetic markers in the localre-gional management of breast cancer. Semin Radiat Oncol. 2002;12:329-340. 167. Morabito A, Magnani E, Gion M, et al. Prognostic and pre-dictive indicators in operable breast cancer. Clin Breast Can-cer. 2003;3:381-390. 168. Rogers CE, Loveday RL, Drew PJ, et al. Molecular prog-nostic indicators in breast cancer. Eur J Surg Oncol. 2002;28:467-478. 169. Rampaul R, Ellis IO, Robertson JFR. Prognostic indices in breast cancer. In: Autier BP, Adebamowo C, Anderson BO, et al, eds. World Breast Cancer Report. iPRI:2012: 323-332. 170. Athanassiadou PP, Veneti SZ, Kyrkou KA, et al. Presence of epidermal growth factor receptor in breast smears of cyst fluids: relationship to electrolyte ratios and pH concentration. Cancer Detect Prev. 1992;16:113-118. 171. Tsutsumi Y, Naber SP, DeLellis RA, et al. Neu oncogene protein and epidermal growth factor receptor are indepen-dently expressed in benign and malignant breast tissues. Hum Pathol."
        },
        {
            "id": "InternalMed_Harrison_8380",
            "title": "InternalMed_Harrison",
            "content": "or low, except in chronic myelomonocytic leukemia. As in aplastic anemia, MDS can be associated with a clonal population of PNH cells. Genetic testing is commercially available for constitutional syndromes."
        },
        {
            "id": "Surgery_Schwartz_9590",
            "title": "Surgery_Schwartz",
            "content": "40%, but the age of onset for carcinoma is typically >50 years old.100 The disorder is characterized by an autosomal dominant pattern of inheritance, with 80% penetrance and variable expres-sion. The incidence is equal in both sexes.Whitcomb and colleagues,101 and separately LeBodic and associates,102 performed gene-linkage analysis and identified a linkage for hereditary pancreatitis to chromosome 7q35. Subse-quently, the region was sequenced and revealed eight trypsino-gen genes. Mutational analysis revealed a missense mutation resulting in an Arg-to-His substitution at position 117 of the cat-ionic trypsinogen gene, or PRSS1, one of the primary sites for proteolysis of trypsin. This gain-of-function mutation results in an excess production of trypsinogen, which results in persistent and uncontrolled proteolytic activity and autodestruction within the pancreas.103 The position 117 mutation of PRSS1 and an addi-tional mutation, now known collectively as the R122H and N291 mutations"
        },
        {
            "id": "InternalMed_Harrison_26919",
            "title": "InternalMed_Harrison",
            "content": "Evaluate and Rx for hyperthyroidism Surgery if indicated with pre-op US for LN assessment Atypia or follicular lesion of undetermined significance (AUS/FLUS) Repeat US-guided FNA or consider molecular testing Surgery if indicated with pre-op US for LN assessment Nondiagnostic NondiagnosticRepeat US-Guided FNA Malignant Suspicious for PTC Follicular neoplasm Consider molecular testing Surgery Benign Follow Pre-op US for LN assessment Close follow-up or surgery Diagnostic US Nodule not functioning Radionuclide scanning Hyperfunctioning nodule Results of FNA cytology History, physical examination, TSH Normal or high TSH Low TSH Bethesda System Cytology Reporting EVALUATION OF THYROID NODULES DETECTED BY PALPATION OR IMAGING Nodule(s) detected on US Do FNA based on US imaging features and size FIGURE 405-13 Approach to the patient with a thyroid nodule. See text and references for details. FNA, fine-needle aspiration; LN, lymph node; PTC, papillary thyroid cancer; TSH, thyroid-stimulating"
        },
        {
            "id": "Psichiatry_DSM-5_3488",
            "title": "Psichiatry_DSM-5",
            "content": "Frequency of Use To track changes in the individual\u2019s symptom severity over time, the measure may be completed at regular intervals as clinically indicated, depending on the stability of the in- dividual\u2019s symptoms and treatment status. Consistently high scores on a particular do- main may indicate significant and problematic areas for the individual that might warrant further assessment, treatment, and follow-up. Clinical judgment should guide decision making. 5355: 583:5 5323 5352:: 525:3 ?:ng .:8 5 tmwugmum S5 .m% 5 .mwaamow 55 .:8 5 .mwufimmw $50 5:65: 5555.38 .85 536855 -55 thifimwaxw .55 5:385:95 5 \u00a305me S2555 2:03:96 5 :oimoaxu 2303 E 3855 Eumw 5 835% Bum: 5 $855 \\EFEmwumxw 39$ 250:0:8 56585 233 \u201cSm #5me D 8835:: cam \u00ab:82: D 2:: 5A .588: D E 885% 289,55\u2014 D 2585 52 D 555E? 025wa .> 9:QO A5395: :2 -:8 59:? 3:888 3:228 5 :2 3:258 5 5:65: 5:55:23 2~E5\u00a7~m 5 532m: 555 $923 55.: 8:33 55:: 0:35 5 E5258 3 2 9:35 5 $55.33 5 :55an 5555 12:5ch _m5fimuuov 523:3 5: 5:955 5:223 :2"
        },
        {
            "id": "Pathoma_Husain_220",
            "title": "Pathoma_Husain",
            "content": "i. Al AT deficiency is due to misfolding of the mutated protein. ii. Mutant AlAT accumulates in the endoplasmic reticulum ofhepatocytes, resulting in liver damage. 111. Biopsy reveals pink, PAS-positive globules in hepatocytes (Fig. 9.9). 4. Disease severity is based on the degree of AlAT deficiency. i. PiM is the normal allele; two copies are usually expressed (PiMM). ii. PiZ is the most common clinically relevant mutation; results in significantly low levels of circulating AlAT iii. PiMZ heterozygotes are usually asymptomatic with decreased circulating levels of AlAT; however, significant risk for emphysema with smoking exists. iv. PiZZ homozygotes are at significant risk for panacinar emphysema and cirrhosis. Fig. 9.7 Chronic bronchitis. Fig. 9.8 Emphysema. A, Gross appearance. B, Microscopic appearance. (A, Courtesy of Yale Rosen, MD) E. Clinical features of emphysema include 1. Dyspnea and cough with minimal sputum 2."
        },
        {
            "id": "Gynecology_Novak_7568",
            "title": "Gynecology_Novak",
            "content": "Table 38.1 Types of Vulvar Cancer cancer of the vulva, reported at 2.5% to 7.2% with a median follow-up of 4.7 to 6.2 years (18\u201320). Supportive evidence that some of these lesions could be precancerous comes from molecular studies that demonstrate aneuploid DNA content, p53 overexpression, high Ki67 expression, indicating high proliferation indices and monoclonal expansion of keratinocytes in lichen sclerosus and associated squamous hyperplasia (21\u201323). An area of active research explores whether treatment of lichen sclerosus with superpotent topical steroids can impact the malignancy risk (18\u201320). Some studies reported vulvar cancer to be more common in patients who are obese, have hypertension and diabetes mellitus, or are nulliparous, but a case-control study of vulvar cancer did not confirm any of these as risk factors (15,24,25). Types of Invasive Vulvar Cancer The histologic subtypes of invasive vulvar cancer are shown in Table 38.1."
        },
        {
            "id": "Pharmacology_Katzung_4911",
            "title": "Pharmacology_Katzung",
            "content": "These disorders usually manifest in childhood as rickets and hypophosphatemia, although they may first present in adults. In both X-linked and autosomal dominant hypophosphatemia, biologically active FGF23 accumulates, leading to phosphate wasting in the urine and hypophosphatemia. In autosomal dominant hypophosphatemia, mutations in the FGF23 gene replace an arginine required for proteolysis and result in increased FGF23 stability. X-linked hypophosphatemia is caused by mutations in the gene encoding the PHEX protein, an endopeptidase. Initially, it was thought that FGF23 was a direct substrate for PHEX, but this no longer appears to be the case. Tumor-induced osteomalacia is a phenotypically similar but acquired syndrome in adults that results from overexpression of FGF23 in tumor cells. The current concept for all of these diseases is that FGF23 blocks the renal uptake of phosphate and blocks 1,25(OH)2D production leading to rickets in children and osteomalacia in adults. Phosphate"
        },
        {
            "id": "InternalMed_Harrison_9637",
            "title": "InternalMed_Harrison",
            "content": "In addition to clinical diagnostic applications, novel genomic technologies, including whole-genome sequencing, are being applied to clinical research specimens with a goal of identifying new pathogens in a variety of circumstances. The tremendous sensitivity and unbiased nature of sequencing is also ideal in searching clinical samples for unknown or unsuspected pathogens."
        },
        {
            "id": "Surgery_Schwartz_3809",
            "title": "Surgery_Schwartz",
            "content": "This is especially pos-sible if the individual tested developed breast cancer close to the age of onset of the general population (age 60 years or older) rather than before age 50 years, as is characteristic of BRCA mutation carriers. Overall, the false-negative rate for BRCA mutation testing is <5%. Some test results, especially when a single base-pair change (missense mutation) is identified, may be difficult to interpret. This is because single base-pair changes do not always result in a nonfunctional protein. Thus, missense mutations not located within critical functional domains, or those that cause only minimal changes in protein structure, may not be disease associated and are usually reported as indetermi-nate results. In communicating indeterminate results to women, care must be taken to relay the uncertain cancer risk associ-ated with this type of mutation and to emphasize that ongoing research might clarify its meaning. In addition, testing other family members with breast"
        },
        {
            "id": "Gynecology_Novak_7385",
            "title": "Gynecology_Novak",
            "content": "teratomas categorized as either low grade or high grade (377). Immature ovarian teratomas may be associated with gliomatosis peritonei, a favorable prognostic finding if composed of completely mature tissues; reports using molecular methods indicate these glial implants are not tumor derived but represent teratomainduced metaplasia of pluripotent m\u00a8ullerian stem cells in the peritoneum (382,383)."
        },
        {
            "id": "Pharmacology_Katzung_4823",
            "title": "Pharmacology_Katzung",
            "content": "elevated phosphate and 1,25(OH)2D. FGF23 is normally inactivated by cleavage at an RXXR site (amino acids 176\u2013179). Mutations in this site lead to excess FGF23, the underlying problem in autosomal dominant hypophosphatemic rickets. A similar disease, X-linked hypophosphatemic rickets, is due to mutations in PHEX, an endopeptidase, which initially was thought to cleave FGF23. However, this concept has been shown to be invalid, and the mechanism by which PHEX mutations lead to increased FGF23 levels remains obscure. FGF23 binds to FGF receptors (FGFR) 1 and 3c in the presence of the accessory receptor Klotho-\u03b1. Both Klotho and the FGFR must be present for signaling in most tissues, although high levels of FGF23 appear to affect cardiomyocytes lacking Klotho. Mutations in Klotho disrupt FGF23 signaling, resulting in elevated phosphate and 1,25(OH)2D levels, a phenotype quite similar to inactivating mutations in FGF23 or GALNT3. FGF23 production is stimulated by 1,25(OH)2D and phosphate"
        },
        {
            "id": "InternalMed_Harrison_13134",
            "title": "InternalMed_Harrison",
            "content": "T. whipplei is a weakly staining gram-positive bacillus. Genomic sequence data have revealed that the organism has a small (<1-megabase) chromosome, with many biosynthetic pathways absent or incomplete. This finding is consistent with a host-dependent intracellular pathogen or a pathogen that requires a nutritionally rich extracellular environment. A genotyping scheme based on a variable region has disclosed more than 70 genotypes (GTs) to date. GTs 1 and 3 are most commonly reported, but all GTs appear to be capable of causing similar clinical syndromes."
        },
        {
            "id": "Surgery_Schwartz_9591",
            "title": "Surgery_Schwartz",
            "content": "uncontrolled proteolytic activity and autodestruction within the pancreas.103 The position 117 mutation of PRSS1 and an addi-tional mutation, now known collectively as the R122H and N291 mutations of PRSS1, account for about two-thirds of cases of hereditary pancreatitis. Masson and associates described a gain-of-function mutation in the anionic trypsinogen gene, PRSS2, that is also present in some cases.104Similarly, SPINK1, an inflammation-induced trypsin inhibitor secreted in acinar cells, has been found to have a role in hereditary pancreatitis. SPINK1 specifically inhibits trypsin action by competitively blocking the active site of the enzyme. Witt and colleagues investigated96 unrelated children with chronic pancreatitis in Germany and found a variety of SPINK1 mutations in 23% of the patients.105 Several studies have now confirmed an association of loss-of-function SPINK1 mutations with familial and idiopathic forms of chronic pancreatitis, as well as so-called tropical"
        },
        {
            "id": "Gynecology_Novak_2971",
            "title": "Gynecology_Novak",
            "content": "Human Papillomavirus The cytologic changes of HPV were first recognized by Koss and Durfee in 1956 and given the term koilocytosis (6). Their significance was not recognized until 20 years later, when Meisels and colleagues reported these changes in mild dysplasia (7) (Fig. 19.6). Molecular biologic studies showed high levels of HPV DNA and capsid antigen, indicating productive viral infection in these koilocytic cells (8). The HPV genome is found in all grades of cervical neoplasia (9). Infection with HPV is the primary cause of cervical cancer (10). As the CIN lesions become more severe (Fig. 19.7), the koilocytes disappear, the HPV copy numbers decrease, and the capsid antigen disappears, indicating that the virus is not capable of reproducing in less differentiated cells (11). Instead, portions of the HPV DNA become integrated into the host cell. Integration of the transcriptionally active DNA into the host cell appears to be essential for malignant transformation (12). Malignant"
        },
        {
            "id": "InternalMed_Harrison_30522",
            "title": "InternalMed_Harrison",
            "content": "6p22-p23 with CAG repeats (exonic); leucine-rich acidic nuclear protein (LANP), region-specific interaction protein 12q23-q24.1 with CAG repeats (exonic) 14q24.3-q32 with CAG repeats (exonic); codes for ubiquitin protease (inactive with polyglutamine expansion); altered turnover of cellular proteins due to proteosome dysfunction 16q22.1-ter; pleckstrin homology domain-containing protein, family G, member 4 (PLEKHG4; puratrophin-1: Purkinje cell atrophy associated protein-1, including spectrin repeat and the guanine-nucleotide exchange factor, GEF for Rho GTPases) 11p12-q12; \u03b2-III spectrin mutations; (SPTBN2); stabilizes glutamate transporter EAAT4; descendants of President Abraham Lincoln 19p13.2 with CAG repeats in \u03b11A-voltage\u2013dependent calcium channel gene (exonic); CACNA1A protein, P/Q type calcium channel subunit 3p14.1-p21.1 with CAG repeats (exonic); ataxin-7; subunit of GCN5, histone acetyltransferase-containing complexes; ataxin-7 binding protein; Cbl-associated protein (CAP;"
        },
        {
            "id": "InternalMed_Harrison_10539",
            "title": "InternalMed_Harrison",
            "content": "As with PBP, culture of dialysate fluid in blood culture bottles improves the yield. To facilitate diagnosis, several hundred milliliters of removed dialysis fluid should be concentrated by centrifugation before culture."
        },
        {
            "id": "InternalMed_Harrison_6060",
            "title": "InternalMed_Harrison",
            "content": "Because of the inherent problems of genetic testing such as cost, The discovery of cancer susceptibility genes raises the possibility of specificity, and sensitivity, it is not yet appropriate to offer these tests to DNA testing to predict the risk of cancer in individuals of affected fam-the general population. However, testing may be appropriate in some ilies. An algorithm for cancer risk assessment and decision making in subpopulations with a known increased risk, even without a defined high-risk families using genetic testing is shown in Fig. 101e-6. Once family history. For example, two mutations in the breast cancer susa mutation is discovered in a family, subsequent testing of asymptom-ceptibility gene BRCA1, 185delAG and 5382insC, exhibit a sufficiently atic family members can be crucial in patient management. A nega-high frequency in the Ashkenazi Jewish population that genetic testing tive gene test in these individuals can prevent years of anxiety in the of an individual of"
        },
        {
            "id": "Pharmacology_Katzung_1970",
            "title": "Pharmacology_Katzung",
            "content": "Although they remain less effective than inhaled corticosteroids, a 5-LOX inhibitor (zileuton) and selective antagonists of the CysLT1 receptor for leukotrienes (zafirlukast, montelukast, and pranlukast; see Chapter 20) are used clinically in mild to moderate asthma. Growing evidence for a role of the leukotrienes in cardiovascular disease has expanded the potential clinical applications of leukotriene modifiers. Conflicting data have been reported in animal studies depending on the disease model used and the molecular target (5-LOX versus FLAP). Human genetic studies demonstrate a link between cardiovascular disease and polymorphisms in the leukotriene biosynthetic enzymes, and indicate an interaction between the 5-LOX and COX-2 pathways, in some populations."
        },
        {
            "id": "InternalMed_Harrison_28373",
            "title": "InternalMed_Harrison",
            "content": "Osteoblastic metastases Abbreviations: PTH, parathyroid hormone; PTHrP, parathyroid hormone\u2013related peptide. of PHEX leads to increased levels of FGF23 has not been determined. 2459 Two rare autosomal recessive hypophosphatemic syndromes associated with elevated FGF23 are due to inactivating mutations of dentin matrix protein-1 (DMP1) and ectonucleotide pyrophosphatase/ phosphodiesterase 1 (ENPP1), both of which normally are highly expressed in bone and regulate FGF23 production. An unusual hypophosphatemic disorder, tumor-induced osteomalacia (TIO), is an acquired disorder in which tumors, usually of mesenchymal origin and generally histologically benign, secrete FGF23 and/or other molecules that induce renal phosphate wasting. The hypophosphatemic syndrome resolves completely within hours to days after successful resection of the responsible tumor. Such tumors typically express large amounts of FGF23 mRNA, and patients with TIO usually exhibit elevations of FGF23 in their blood."
        },
        {
            "id": "InternalMed_Harrison_28658",
            "title": "InternalMed_Harrison",
            "content": "Inheritance and Genetic Defects Multiple defects at the GNAS locus have now been identified in PHP-Ia, PHP-Ib, and PPHP patients. This gene, which is located on chromosome 20q13.3, encodes the \u03b1-subunit of the stimulatory G protein (Gs\u03b1), among other products (see below). Mutations include abnormalities in splice junctions associated with deficient mRNA production, point mutations, insertions, and/or deletion that all result in a protein with defective function resulting in a 50% reduction of Gs\u03b1 activity in erythrocytes or other cells."
        },
        {
            "id": "InternalMed_Harrison_6064",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 101e-5 Germline and somatic mutations in the tumor-suppressor gene APC. APC cancer (human papillomavirus [HPV]; encodes a 2843-amino-acid protein with six major domains: an oligomerization region (O), armadillo Chap. 222), and T cell leukemia (retrepeats (ARM), 15-amino-acid repeats (15 aa), 20-amino-acid repeats (20 aa), a basic region, and a roviruses; Chap. 225e). The mechadomain involved in binding EB1 and the Drosophila discs large homologue (E/D). Shown are the nisms of action of these viruses are positions within the APC gene of a total of 650 somatic and 826 germline mutations (from the APC varied but always involve activation of database at http://www.umd.be/APC). The vast majority of these mutations result in the truncation of growth-promoting pathways or inhithe APC protein. Germline mutations are found to be relatively evenly distributed up to codon 1600 bition of tumor-suppressor products except for two mutation hotspots at amino acids 1061 and 1309, which together"
        }
    ],
    "scores": [
        0.01710319164162015,
        0.01665774685576666,
        0.015802318486882246,
        0.015298175344904316,
        0.015079365079365078,
        0.01487173816895179,
        0.014843410178338408,
        0.01395131086142322,
        0.012426900584795321,
        0.012144294337453291,
        0.009900990099009901,
        0.009900990099009901,
        0.009900990099009901,
        0.00980392156862745,
        0.00980392156862745,
        0.00980392156862745,
        0.009708737864077669,
        0.009708737864077669,
        0.009708737864077669,
        0.009708737864077669,
        0.009615384615384616,
        0.009615384615384616,
        0.009615384615384616,
        0.009615384615384616,
        0.009523809523809525,
        0.009523809523809525,
        0.009523809523809525,
        0.009523809523809525,
        0.009433962264150943,
        0.009433962264150943,
        0.009433962264150943,
        0.009433962264150943
    ],
    "execution_time": 61.361656188964844
}